A phase 1/2 study of REGN5093-M114, a METxMET antibody-drug conjugate, in patients with mesenchymal epithelial transition factor (MET)-overexpressing NSCLC Meeting Abstract
| Authors: | Drilon, A. E.; Awad, M. M.; Gadgeel, S. M.; Villaruz, L. C.; Sabari, J. K.; Perez, J.; Daly, C.; Patel, S.; Li, S.; Seebach, F. A.; Lowy, I.; Magnan, H. D.; Rietschel, P. |
| Abstract Title: | A phase 1/2 study of REGN5093-M114, a METxMET antibody-drug conjugate, in patients with mesenchymal epithelial transition factor (MET)-overexpressing NSCLC |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680305108 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.TPS8593 |
| Notes: | Meeting Abstract: TPS8593 -- This meeting was also held virtually -- Source: Wos |
